Radiation protection in therapy with radiopharmaceuticals

References

• Blumhardt R, Wolin EA, Phillips WT, Salman UA, Walker RC, Stack BC Jr, Metter D. 2014. Current controversies in the initial post-surgical radioactive iodine therapy for thyroid cancer: a narrative review. Endocr Relat Cancer. 21:R473–R484.
   PubMed Web of Science ®Google Scholar
• Bodei L, Pepe G, Paganelli G. 2010. Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues. Eur Rev Med Pharmacol Sci. 14:347–351.
   PubMed Web of Science ®Google Scholar
• Bonnema SJ, Hegedus L. 2012. Radioiodine therapy in benign thyroid diseases: effects, side effects, and factors affecting therapeutic outcome. Endocr Rev. 33:920–980.
   PubMed Web of Science ®Google Scholar
• Burki TK. 2017. 177Lu-Dotatate for midgut neuroendocrine tumours. Lancet Oncol. 18:e74.
   PubMed Web of Science ®Google Scholar
• Chatal JF, Hoefnagel CA. 1999. Radionuclide therapy. Lancet. 354:931–935.
   PubMed Web of Science ®Google Scholar
• Choudhury P, Gupta M. 2017. Personalized & precision medicine in cancer: a theranostic approach. Curr Radiopharm. 10:166–170.
   PubMed Web of Science ®Google Scholar
• Eberlein U, Cremonesi M, Lassmann M. 2017. Individualized dosimetry for theranostics: necessary, nice to have, or counterproductive? J Nucl Med. 58:97S–103S.
   PubMed Web of Science ®Google Scholar
• Flux GD, Verburg FA, Chiesa C, Bardies M, Gleisner KS, Hertz B, Konijnenberg M, Lassmann M, Ljungberg M, Luster M, et al. 2017. Comparison of Empiric Versus Dosimetry-Guided Radioiodine Therapy: The Devil Is in the Details. J Nucl Med. 58:862.
   PubMedGoogle Scholar
• Giammarile F, Muylle K, Delgado Bolton R, Kunikowska J, Haberkorn U, Oyen W. 2017. Dosimetry in clinical radionuclide therapy: the devil is in the detail. Eur J Nucl Med Mol Imaging. 44:1–3.
   Web of Science ®Google Scholar
• Hakala TT, Sand JA, Jukkola A, Huhtala HS, Metso S, Kellokumpu-Lehtinen PL. 2016. Increased risk of certain second primary malignancies in patients treated for well-differentiated thyroid cancer. Int J Clin Oncol. 21:231–239.
   PubMed Web of Science ®Google Scholar
• Hosono M, Ikebuchi H, Nakamura Y, Nakamura N, Yamada T, Yanagida S, Kitaoka A, Kojima K, Sugano H, Kinuya S, et al. 2018. Manual on the proper use of lutetium-177-labeled somatostatin analogue (Lu-177-DOTA-TATE) injectable in radionuclide therapy (2nd ed.). Ann Nucl Med. 32:217–235.
   PubMed Web of Science ®Google Scholar
• ICRP. 2007a. The 2007 recommendations of the international commission on radiological protection. ICRP publication 103. Ann ICRP 37:1–332.
   Google Scholar
• ICRP. 2007b. ICRP Publication 105. Radiation protection in medicine. Ann ICRP 37:1–63.
   Google Scholar
• Kaminski M. 2007. Bexxar, iodine I 131 tositumomab, effective in long-term follow-up of non-Hodgkin's lymphoma. Cancer Biol Ther. 6:996–997.
   PubMed Web of Science ®Google Scholar
• Ko KY, Kao CH, Lin CL, Huang WS, Yen RF. 2015. (131)I treatment for thyroid cancer and the risk of developing salivary and lacrimal gland dysfunction and a second primary malignancy: a nationwide population-based cohort study. Eur J Nucl Med Mol Imaging. 42:1172–1178.
   PubMed Web of Science ®Google Scholar
• Kratochwil C, Bruchertseifer F, Rathke H, Hohenfellner M, Giesel FL, Haberkorn U, Morgenstern A. 2018. Targeted α-therapy of metastatic castration-resistant prostate cancer with 225ac-psma-617: swimmer-plot analysis suggests efficacy regarding duration of tumor control. J Nucl Med. 59:795–802.
   PubMed Web of Science ®Google Scholar
• Luster M, Pfestroff A, Hanscheid H, Verburg FA. 2017. Radioiodine therapy. Semin Nucl Med. 47:126–134.
   PubMed Web of Science ®Google Scholar
• Martinez A, Martinez-Ramirez M, Martinez-Caballero D, Beneit P, Clavel J, Figueroa G, Verdu J. 2017. Radioimmunotherapy for non-Hodgkin's lymphoma; positioning, safety, and efficacy of 90Y-Ibritumomab: 10 years of experience and follow-up. Rev Esp Med Nucl Imagen Mol. 36:13–19.
   PubMed Web of Science ®Google Scholar
• Moek KL, Giesen D, Kok IC, de Groot DJA, Jalving M, Fehrmann RSN, Lub-de Hooge MN, Brouwers AH, de Vries EGE. 2017. Theranostics using antibodies and antibody-related therapeutics. J Nucl Med. 58:83S–90S.
   PubMed Web of Science ®Google Scholar
• Nitipir C, Niculae D, Orlov C, Barbu MA, Popescu B, Popa AM, Pantea AMS, Stanciu AE, Galateanu B, Ginghina O, et al. 2017. Update on radionuclide therapy in oncology. Oncol Lett. 14:7011–7015.
   PubMed Web of Science ®Google Scholar
• Parker C, Heidenreich A, Nilsson S, Shore N. 2018. Current approaches to incorporation of radium-223 in clinical practice. Prostate Cancer Prostatic Dis. 21:37–47.
   PubMed Web of Science ®Google Scholar
• Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fossa SD, Chodacki A, Wiechno P, Logue J, Seke M, et al. 2013. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 369:213–223.
   PubMed Web of Science ®Google Scholar
• Pryma DA, Mandel SJ. 2014. Radioiodine therapy for thyroid cancer in the era of risk stratification and alternative targeted therapies. J Nucl Med. 55:1485–1491.
   PubMed Web of Science ®Google Scholar
• Ron E, Doody MM, Becker DV, Brill AB, Curtis RE, Goldman MB, Harris BS, III HDA, McConahey WM, Maxon HR, et al. 1998. Cancer mortality following treatment for adult hyperthyroidism: cooperative thyrotoxicosis therapy follow-up study group. JAMA. 280:347–355.
   PubMed Web of Science ®Google Scholar
• Rubino C, de Vathaire F, Dottorini ME, Hall P, Schvartz C, Couette JE, Dondon MG, Abbas MT, Langlois C, Schlumberger M. 2003. Second primary malignancies in thyroid cancer patients. Br J Cancer. 89:1638–1644.
   PubMed Web of Science ®Google Scholar
• Seidlin SM, Marinelli LD, Oshry E. 1946. Radioactive iodine therapy; effect on functioning metastases of adenocarcinoma of the thyroid. J Am Med Assoc. 132:838–847.
   PubMed Web of Science ®Google Scholar
• Sgouros G, Hobbs RF, Song H. 2011. Modelling and dosimetry for alpha-particle therapy. Curr Radiopharm. 4:261–265.
   PubMedGoogle Scholar
• Sgouros G, Roeske JC, McDevitt MR, Palm S, Allen BJ, Fisher DR, Brill AB, Song H, Howell RW, Akabani G, et al. 2010. MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy. J Nucl Med. 51:311–328.
   PubMed Web of Science ®Google Scholar
• Siegel E. 1999. The beginnings of radioiodine therapy of metastatic thyroid carcinoma: a memoir of samuel m. seidlin, m. d. (1895–1955) and his celebrated patient. Cancer Biotherapy and Radiopharmaceuticals. 14:71–79.
   PubMed Web of Science ®Google Scholar
• Stokke C, Gabina PM, Solny P, Cicone F, Sandstrom M, Gleisner KS, Chiesa C, Spezi E, Paphiti M, Konijnenberg M, et al. 2017. Dosimetry-based treatment planning for molecular radiotherapy: a summary of the 2017 report from the internal dosimetry task force. EJNMMI Phys. 4:27.
   PubMed Web of Science ®Google Scholar
• Strosberg J, Krenning E. 2017. 177Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 376:1391–1392.
   PubMedGoogle Scholar
• Wagner HN Jr, Wiseman GA, Marcus CS, Nabi HA, Nagle CE, Fink-Bennett DM, Lamonica DM, Conti PS. 2002. Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with (90)Y-labeled anti-CD20 monoclonal antibody. J Nucl Med. 43:267–272.
   PubMed Web of Science ®Google Scholar
• Wiseman GA, Kornmehl E, Leigh B, Erwin WD, Podoloff DA, Spies S, Sparks RB, Stabin MG, Witzig T, White CA. 2003. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. J Nucl Med. 44:465–474. eng.
   PubMed Web of Science ®Google Scholar
• Witzig TE, Molina A, Gordon LI, Emmanouilides C, Schilder RJ, Flinn IW, Darif M, Macklis R, Vo K, Wiseman GA. 2007. Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer. 109:1804–1810.
   PubMed Web of Science ®Google Scholar
• Zukotynski K, Jadvar H, Capala J, Fahey F. 2016. Targeted radionuclide therapy: practical applications and future prospects. Biomark Cancer. 8:35–38.
   PubMedGoogle Scholar